NASDAQ: AVBP
Arrivent Biopharma Inc Stock Ownership - Who owns Arrivent Biopharma?

Insider buying vs selling

Have Arrivent Biopharma Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Hillhouse Investment Management Ltd10% Owner2025-12-10555,555$23.37
$12.98MSell

1 of 1

AVBP insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AVBP insiders and whales buy or sell their stock.

AVBP Shareholders

What type of owners hold Arrivent Biopharma Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Hillhouse Investment Management Ltd7.97%3,929,117$116.85MInsider
James Healy3.44%1,696,752$50.46MInsider
Carl L. Gordon3.07%1,513,664$45.02MInsider
Orbimed Advisors LLC3.07%1,513,664$45.02MInsider
Zhengbin Yao1.24%613,138$18.23MInsider
Robin Lachapelle1.08%530,213$15.77MInsider
Stuart Lutzker0.30%147,744$4.39MInsider
James Paul Kastenmayer0.01%7,386$219.66kInsider
Suvret0.01%4,516$134.31kInstitution
Montanova Capital LLC0.01%4,515$134.28kInstitution

1 of 3

AVBP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AVBP0.09%20.18%Net Selling
BCAX0.11%31.92%Net BuyingNet Selling
AAPG0.00%26.79%
INVA0.10%69.14%Net BuyingNet Selling
OMER0.05%5.73%Net BuyingNet Buying

Arrivent Biopharma Stock Ownership FAQ

Who owns Arrivent Biopharma?

Arrivent Biopharma (NASDAQ: AVBP) is owned by 0.09% institutional shareholders, 20.18% Arrivent Biopharma insiders, and 79.72% retail investors. Hillhouse Investment Management Ltd is the largest individual Arrivent Biopharma shareholder, owning 3.93M shares representing 7.97% of the company. Hillhouse Investment Management Ltd's Arrivent Biopharma shares are currently valued at $119.13M.

If you're new to stock investing, here's how to buy Arrivent Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.